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Background Chronic respiratory diseases (CRDs) contribute signifi-
cantly towards the global burden of disease, but the true prevalence 
and burden of these conditions in adults is unknown in the majority 
of low- and middle-income countries (LMICs). We aimed to identify 
strategies – in particular the definitions, study designs, sampling frames, 
instruments, and outcomes – used to conduct prevalence surveys for 
CRDs in LMICs. The findings will inform a future RESPIRE Four Coun-
try ChrOnic Respiratory Disease (4CCORD) study, which will estimate 
CRD prevalence, including disease burden, in adults in LMICs.
Methods We conducted a scoping review to map prevalence surveys 
conducted in LMICs published between 1995 and 2018. We followed 
Arksey and O’Malley’s six-step framework. The search was conducted 
in OVID Medline, EMBASE, ISI Web of Science, Global Health, WHO 
Global Index Medicus and included three domains: CRDs, prevalence 
and LMICs. After an initial title sift, eight trained reviewers undertook 
duplicate study selection and data extraction. We charted: country and 
populations, random sampling strategies, CRD definitions/phenotypes, 
survey procedure (questionnaires, spirometry, tests), outcomes and as-
sessment of individual, societal and health service burden of disease.
Results Of 36 872 citations, 281 articles were included: 132 from Asia 
(41 from China). Study designs were cross-sectional surveys (n = 260), 
cohort studies (n = 11) and secondary data analysis (n = 10). The num-
ber of respondents in these studies ranged from 50 to 512 891. Asth-
ma was studied in 144 studies, chronic obstructive pulmonary disease 
(COPD) in 112. Most studies (100/144) based identification of asthma 
on symptom-based questionnaires. In contrast, COPD diagnosis was 
typically based on spirometry findings (94/112); 65 used fixed-ratio 
thresholds, 29 reported fixed-ratio and lower-limit-of-normal values. 
Only five articles used the term ‘phenotype’. Most studies used ques-
tionnaires derived from validated surveys, most commonly the Europe-
an Community Respiratory Health Survey (n = 47). The burden/impact 
of CRD was reported in 33 articles (most commonly activity limitation).
Conclusion Surveys remain the most practical approach for estimating 
prevalence of CRD but there is a need to identify the most predictive 
questions for diagnosing asthma and to standardise diagnostic criteria.
Cite as: Hanafi NS, Agarwal D, Chippagiri S, Brakema EA, Pinnock H, Sheikh A, Liew 
SM, Ng CW, Isaac R, Chinna K, Wong LP, Hussein N, Abu Bakar AI, Pang YK, Juvekar 
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Chronic respiratory diseases (CRDs) contribute significantly to the national, regional and global burden of dis-
ease [1]. Although the morbidity and mortality of such conditions are estimated to be high in low- and mid-
dle-income countries (LMICs), there is concern that there is little robust data on the true prevalence of asthma 
and chronic obstructive pulmonary disease (COPD) in these countries [2,3]. Accurate data on prevalence, in-
cluding disease burden, are needed to inform health care policy on prioritising care and targeting risk factors 
particularly for conditions that are preventable and treatable in primary care.
CRD encompasses several conditions. Most common are asthma and COPD; but others such as bronchiecta-
sis, post-tuberculosis, interstitial lung disease and lung cancer are potentially important causes of morbidity in 
LMICs. In poorly-resourced primary health care systems in LMICs the conditions often remain undiagnosed 
as limited access to health care is compounded by insufficient attention to the conditions and lack of diagnos-
tic capabilities in the facilities [4,5]. Determining the prevalence of asthma and COPD in the community re-
mains a challenge because of the poor sensitivity and specificity of widely used questionnaire-based research 
tools [3,6]. Objective testing with spirometry may be a challenge in community-based epidemiological sur-
veys [7], particularly in LMICs.
Scoping reviews are used to map the literature available and to identify potential gaps in the evidence base [8]. 
We conducted a systematic scoping review on the prevalence of CRDs to address the following questions with 
respect to prevalence studies on CRDs:
1.  What surveys on the prevalence of asthma, COPD and other CRDs have been undertaken in LMICs?
2.  What definitions, questionnaires, tests, diagnostic processes and outcomes for CRDs did the sur-
veys employ?
3.  How was the socio-economic burden (from a societal or healthcare perspective) of asthma, COPD 
and other CRDs estimated in these surveys?
4.  What strategies have been used to identify phenotypes of asthma and COPD, or to identify the caus-
es of ‘other CRD’?
We intend to use the findings of this scoping review to inform the methodology of a proposed RESPIRE survey 
in 4 Countries estimating prevalence and burden of Chronic Respiratory Disease in adults in LMICs [4CCORD 
study].
METHODS
We followed the six-step framework for undertaking scoping reviews described by Arksey and O’Malley [9] 
which has been widely employed [10,11]. The full protocol for this systematic scoping review has been pub-
lished [12]. The research questions and methods are summarised below.
Search strategy
We developed a comprehensive search strategy assisted by information librarians. The search strategy (MED-
LINE search strategy detailed in Table S1 in the Online Supplementary Document) comprised of keywords 
and subject headings (eg, MeSH) that were used to identify studies within three domains – CRDs, prevalence 
(including ‘burden’ or ‘cost’ in the title/abstract) and LMICs. The strategy was first conducted in OVID MED-
LINE. We then tailored and applied the strategy in EMBASE, ISI WoS, Global Health and WHO Global Index 
Medicus. We included studies published between 1995, when the Global Initiative on Asthma (GINA) was 
launched [13], and 2018. We did not limit our search to any language.
Study selection
We included articles reporting community-based prevalence studies of CRDs that were published in academ-
ic journals. Eight members of the research team were involved in the initial study selection. As a scoping re-
view, our search criteria were sensitive rather than specific. We anticipated many hits, so we carried out the 
selection process in three stages:
•  A single reviewer performed initial title sift to exclude obviously irrelevant titles. Two reviewers (DA, 
NSH) conducted this individually on separate parts of the dataset.
•  Screening of titles and abstracts (DA and NSH worked on separate datasets)
•  Full text screening of potentially relevant articles (DA, NSH, HP, SC, SS or EAB)
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To ensure better understanding of the studies’ meth-
odological framework, at each stage we undertook a 
training process of duplicate screening of 200 cita-
tions. We compared initial decisions, resolved dis-
agreements, and refined the inclusion and exclusion 
criteria in discussion with three arbiters (HP, EMK 
and SJ). This was repeated until we were satisfied 
that the selection criteria were clear, and research-
ers were achieving at least 90% agreement. At all 
stages, articles were grouped according to their rele-
vance (relevant, not relevant or unsure); researchers 
were instructed to use an ‘unsure’ category if there 
was any doubt about relevance and these articles 
were then discussed within the team and a decision 
made. The selection criteria and definitions applied 
are detailed in Table 1 [12].
Data charting
In line with scoping review methodology, we did 
not assess the quality of the individual studies be-
cause we aimed to map the evidence and not to 
summarise the study results nor to analyse disease 
risks and prevalence rates. We piloted and refined a 
customised data extraction form. Six reviewers (DA, 
NSH, SC, SS, HP or EAB) independently extracted 
data into the extraction form. Any ambiguities were 
resolved within the group. Studies from the same 
study population were reported as independent 
studies, with reference to the main article if indicat-
ed. Our research questions focused on identifying 
the process (rather than the outcomes) of undertak-
ing surveys of CRD in LMICs. We made one attempt 
to contact authors of included articles for additional 
information, copies of questionnaires or study pro-
cedures if they were not otherwise available.
Summarising and reporting the results
We summarised the data focusing on: 1) the strategies used to identify randomly sampled populations in 
LMICs; 2) the disease definitions used (which may vary over time); 3) the questionnaires used and tests per-
formed to detect asthma, COPD and/or other CRDs; 4) the individual, societal and health care burden of CRD, 
and the risk factors for disease and 5) surveys that addressed contemporary understanding of asthma/COPD 
phenotypes. We held an investigators’ meeting with RESPIRE partners (from Bangladesh, India, Malaysia, Pa-
kistan and Edinburgh, UK), where we discussed the findings. We followed the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses extension for. Scoping Reviews (PRISMA-ScR) [17].
RESULTS
The literature search yielded 36 872 citations from five databases. After screening 729 full text articles, 281 
were included in this scoping review (Figure 1). The study characteristics are detailed in Table S2 in the On-
line Supplementary Document.
Question 1: What surveys on the prevalence of asthma, COPD and other CRDs 
have been undertaken in LMICs?
The 281 publications on CRD prevalence surveys in LMCs, published between 1995 and 2018, report-
ed studies conducted in a total of 70 countries. Most publications were based on surveys conducted in 
Asia (n = 133 publications) with China, India and Turkey having 42, 35 and 30 publications, respectively 
Table 1. Inclusion and exclusion criteria [12].
Criterion Inclusion and exclusion criteria
Population We included surveys on general populations of adults (typically 
≥18 years but used different thresholds according to age of ma-
jority which may vary in different countries). Surveys that includ-
ed both adults and children were included but those that focused 
entirely on children were excluded. We excluded surveys on pop-
ulations with known CRDs or respiratory diseases symptoms (for 
example: attendees at a respiratory clinic).
Screening procedure We included surveys that determined the prevalence of asthma, 
COPD or other CRD using questionnaires, clinical examination, 
spirometry and/or other tests. We also included the prevalence of 
chronic respiratory symptoms and phenotypes.
Disease definitions We included surveys that used definitions of CRD from globally 
recognised guidelines: asthma [14], COPD [15] or other CRD [7]. 
We defined ‘chronic’ respiratory symptoms as symptoms (such 
as cough, wheezing and shortness of breath) that have persisted 
for more than three months, or recurred in ‘attacks’. We did not 
include surveys on acute respiratory conditions such as pneumo-
nia or active TB, therapeutic interventions, pharmaco-economics/
cost analyses of medication or specific treatments, quality of dis-
ease management, assessment of inhaler technique, comparison 
between drug regimens, and health economic analyses (though 
we included prevalence studies that included assessments of so-
cio-economic burden (eg, CRD-related time off work).
Burden of disease We included population-level surveys of symptom burden, use 
of health care resources or societal burden (eg, absenteeism, loss 
of earnings).
Phenotypes We included surveys that detected phenotypes of asthma, COPD 
or the overlap between these conditions.
Setting We focused our review on low- or middle-income countries 
(LMICs) classified by the Organisation for Economic Cooperation 
and Development at the time of the survey. We included surveys 
in high-income countries only if the survey was also conducted 
in LMICs, eg, the BOLD study [16].
Study design We included population or community surveys that aimed to 
determine the prevalence of one or more CRDs. The survey 
procedures included questionnaires, clinical examination, lung 
function tests (spirometry) or other tests (skin prick tests). We 
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(Table S1 in the Online Supplementary Document). This is followed by publications reported from the Af-
rican (n = 45) and European continents (n = 39) (Figure 2). The number of publications reporting the prev-
alence of CRDs increased steadily over the years, from 11 between 1995-1999 to 98 between 2015-2018. 
Some studies, such as the BOLD study [16], was carried out in high-income countries as well as LMICs.
Figure 1. Preferred Reporting Items for Systematic Reviews And Meta-Analyses (PRISMA) flowchart for study selection process.
Figure 2. Distribution of chronic respiratory disease prevalence studies.
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Of the 281 publications, 181 sampled from general populations, 57 recruited specific groups (clinic at-
tendees or staff, university students and staff, elderly, women, men, athletes, smokers, non-smokers, ab-
original people and those with family history of asthma) and 43 were based on occupational groups. In 
this review, only surveys that screened for asthma, COPD and/or other CRDs were included. Surveys for 
specific occupational lung disease were excluded. Details are in Table S2 in the Online Supplementary 
Document.
The study designs of the 281 studies varied: cross-sectional surveys (n = 260), cohort surveys (n = 11) and sec-
ondary data analyses (n = 10). The cross-sectional surveys were typically house-to-house or community sur-
veys (n = 178), at worksites (n = 40), surveys in clinics or health care facilities (n = 20), in universities (n = 8), 
telephone (n = 7) and postal surveys (n = 3); one postal survey was followed by a house-to-house survey due 
to initial low response rate.
The number of respondents in each study ranged from 50 to 512 891. Ten publications reported sample siz-
es of 100 000 or more; five in India [18-22], three in China [23-25] and two in multiple countries [26,27]. 
101 studies had fewer than 1000 respondents. Response rates were reported in 128 surveys, out of which 91 
achieved at least 80%.
Question 2. What definitions, questionnaires, tests and diagnostic processes and 
outcomes for CRDs did the surveys employ?
Definition of diseases
Surveys used various definitions for both asthma and COPD. 
Figure 3 contrasts the approach for asthma and COPD.
For asthma diagnosis, most surveys used self-reported di-
agnosis (n = 98), or a questionnaire survey of symptoms 
(n = 97). Other methods were use of asthma medication 
(n = 35), spirometry (n = 26), verification through records 
(n = 8) and reference to GINA guidelines (n = 5). These meth-
ods were sometimes used in combination.
In marked contrast, for COPD diagnosis, 90 articles based 
the diagnosis on spirometry. Of these, 59 were based on a 
fixed Forced Expiratory Volume in one second/Forced Vital 
Capacity (FEV1/FVC) ratios, 28 used both fixed ratios and lower limits of normal (LLN) and three used only 
lower limit of normal as diagnostic criteria. Lower limit of normal was used in more recent studies (published 
since 2008). Other methods, which were sometimes used in combination, were according to GOLD guide-
lines (n = 87), symptoms (n = 44), self-reported diagnosis (n = 14) and doctor’s diagnosis, verified through re-
cords (n = 3).
Questionnaires
 Most studies used validated questionnaires such as the European Community Respiratory Health Survey 
(ECRHS) (n = 58), American Thoracic Society Respiratory Questionnaire (ATS) (n = 43), International Union 
against Tuberculosis and Lung Disease (IUATLD) (n = 23) and the Medical Research Council Respiratory Ques-
tionnaire (MRC) (n = 14), either in totality, adapted or modified. The BOLD (n = 30) and PLATINO (n = 12) 
surveys used questionnaires derived from both the ECRHS and ATS questionnaires.
Common symptoms explored in the surveys were cough, wheezing, expectoration, dyspnea, breathlessness or 
phlegm as well nasal symptoms of itching, obstruction, sneezing, and secretion.
Spirometry or peak flow meter
Baseline spirometry was measured in 167 studies; of these, 109 also reported post-bronchodilator readings, 
usually to salbutamol (albuterol) in doses ranging from 100 to 400 µg. Two surveys used ipratropium and two 
used CombiventTM. Most studies reported on spirometry findings of obstructive patterns; only 22 studies re-
ported prevalence of restriction. One study included chest x-ray findings to measure the prevalence of pneu-
moconiosis [28]. Two studies carried out in Malawi and Thailand [29,30] reported prevalence of restrictive 
lung disease using European normal values that could be an overestimation while four studies used modified 
values or lower limits of normal to suit local population [31-34].
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Peak flow was measured in 13 surveys. Of these, five measured only peak flow without doing spirometry; 
four were worksite surveys [35-38] and one was a community survey exploring the effects of air quality [39].
Other diagnostic tests (each reported in one study) included exhaled CO level, DNA extraction, genetic bio-
markers, pollution monitoring, RAST test, rhinomanometry, residue concentrations of pesticides in urine, se-
rum assay for C pneumoniae, urine cotinine as well as water contact and fecal contaminants.
Outcomes
Most of the studies (n = 187) reported the prevalence of spe-
cific disease(s), though a minority reported symptoms or lung 
function test (Table 2). Asthma was the most common dis-
ease studied (n = 144) followed by COPD (n = 112); 22 articles 
reported the prevalence of both asthma and COPD. Asthma 
COPD Overlap Syndrome (ACOS) was specifically explored in two recent surveys [40,41].
Question 3. How was the socio-economic burden (from a societal or health care 
perspective) of asthma, COPD and other CRDs estimated in these surveys?
Burden (or impact) of respiratory disease was reported in only 33 publications. The most common variable 
was activity limitation (n = 22) followed by quality of life (n = 13), work absenteeism (n = 12) and psychosocial 
distress (n = 5). Our search strategy focussed on prevalence studies and although we included ‘cost’ as a word 
in the title or abstract, we did not use search terms for economic evaluation of the diseases. Health care utili-
sation, and health status were reported in 10 and 8 studies, respectively.
Question 4. What strategies have been used to identify phenotypes of asthma and 
COPD, or to identify the causes of ‘other CRD’?
COPD was linked to either environmental factors (n = 60) or occupation (n = 32). Only five articles (four of 
which were published in the last 10 years) specifically used the term ‘phenotype’ when describing different 




We identified 281 publications reporting community surveys employing diverse methods for assessing the 
prevalence of CRDs in general populations in LMICs. The studies were conducted in 70 countries; nearly 
half were from Asia. Ten articles reported surveys with more than 100 000 respondents; 101 studies had 
fewer than 1000 respondents. Surveys typically focussed on detecting either asthma (122 studies) or COPD 
(90 studies). 22 studies explicitly aimed to identify both conditions and very few detected ‘other CRDs’. 
Most studies used questionnaires derived from validated surveys (most commonly the ECRHS). Detection 
of asthma was typically based on symptoms or self-reported diagnosis. In contrast, COPD diagnosis was 
based on demonstration of obstruction on spirometry (without consideration of symptoms in 55%). The 
burden of CRD was reported in 33 publications, most commonly activity limitation. Only five recent arti-
cles used the term ‘phenotype’.
Interpretation with reference to other literature
Prevalence estimates depend on the methods and diagnostic criteria used [46]. This was previously highlighted 
in a systematic review done in Europe [47] which showed that reported epidemiological estimates varied due 
to different methods including study designs. The most popular design used for studying disease prevalence 
in the community was household surveys. Postal surveys were not useful due to poor response rate [48-50], 
and one study found that the postal questionnaires were completed by persons other than the individual in-
vited [48]. There was evidence that some surveys included quality measures, such as careful population-based 
sampling, standardised spirometry equipment, training and monitoring of spirometry technicians; over-read-
ing of spirometry reports and strict protocols for questionnaire [16].
Table 2. Study outcomes
Outcome Number, n (%)
Disease only 187 (67)
Combination of disease, symptom and/or lung function 57 (21)
Symptoms only 22 (8)
Lung function only 15 (5)
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The studies in this review used a variety of operational definitions for asthma and COPD, employed a range 
of instruments, and modes of data collection although the increasing number of multi-country studies (eg, 
BOLD [16], PLATINO [51], PUMA [52], BREATHE [53]) have begun to standardize disease definitions. COPD 
guidelines are clear that a diagnosis of COPD relies on the demonstration of obstructive spirometry in a pa-
tient with chronic respiratory symptoms [54,55], yet 57 out of 112 studies in this review equated obstructive 
spirometry with COPD with no consideration of whether the patient had symptoms.
In contrast, the range of methods used to detect asthma reflects current discussions about the best way to 
confirm a diagnosis of asthma in clinical practice [56,57]. In LMICs, it has been suggested that the presence 
of asthma is better detected by having three components to the diagnosis, ie, presence of symptoms, reported 
physician-diagnosis, use of medication [26]. However, these approaches are often limited by inaccurate recall 
and recent studies have questioned the accuracy of physician diagnosis [58]. We found examples of all three 
of these approaches, but with little evidence of an emerging consensus, which makes it difficult to compare 
results across studies.
Spirometry
In our review, 167 surveys conducted spirometry to define airway obstruction, but variation in the conduct of 
the test and interpretation of results means that the findings are not comparable.
The optimal threshold for diagnosing airflow obstruction has been hotly debated for some years [46] and guide-
lines make different recommendations [13,54,59]. Almost all the early surveys in our review, including multina-
tional BOLD and PLATINO studies, used a fixed ratio of <70% as the diagnostic threshold for obstruction, aligned 
with global COPD guideline recommendations [16,54]. This however would underestimate the prevalence of 
COPD in young populations (for example, in the FRESH AIR study in Uganda where women exposed to biomass 
fuel since childhood had severe obstruction by the age of 35 [60]) and overestimate the prevalence of COPD in 
older populations [61-63]. The use of the LLN instead of a fixed criterion was advocated in 2004 [64], and in our 
review, studies conducted after 2008 started to use LLN, often reporting both. Use of LLN requires robust normal 
values from the relevant population which are not always available for LMIC countries [65], a challenge addressed 
in a study from Nigeria in which local normal values were derived from the non-smoking study population [66].
Discrepancies also arose because only two thirds of the studies used the recommended post-bronchodilator 
spirometry results, which could make considerable difference to the defined prevalence of airway obstruction 
[67]. A challenge, which is not yet reflected in the studies, is the recent change to the ATS/ERS standards re-
quiring an inspiratory loop to assess for full inspiration to reduce the risk of mis-diagnosis of restrictive dis-
orders [59]. This will incur the additional cost of providing filters to ensure safe practice in LMICs, many of 
which have endemic TB.
Evidence gaps and implications for future surveys in LMICs
Although surveys (questionnaires and lung function) remain the most practical approach for estimating prev-
alence of CRD, our scoping review has identified several evidence gaps which should be considered in future 
CRD surveys in LMICs:
•  Many surveys focused on detecting one condition (asthma or COPD) only; a few identified both, but 
hardly any mentioned other CRDs.
•  In line with current moves to personalised medicine [68], a few recent surveys have begun to con-
sider phenotypes of asthma and COPD, but none used FeNO, which is gaining importance in phe-
notyping asthma [69].
•  Algorithms for making a clinical diagnosis (as opposed to recording lung function) were often not well 
formulated, especially for asthma where the most predictive questions for the diagnosis are not clear.
•  Although respiratory symptoms were assessed in most surveys, and many of the questionnaires used 
included impact on work and social activities, the impact on the quality of life of individuals, or the 
social and economic burden were rarely reported.
Strengths and limitations
As this was a scoping review, it is useful for mapping common methodologies and identifying gaps in literature. 
However, no conclusions can be drawn on the quality of those studies. We focused on the methodologies used 
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Despite an inclusive search strategy and 36 872 hits, we may have missed some relevant studies. We did not 
include LILACS or Chinese language databases; however, our searches detected 30 and 42 studies conducted 
in South American countries (Argentina, Brazil, Chile, Colombia, Peru, Uruguay and Venezuela) and China 
respectively (Table S2 in the Online Supplementary Document). We did not impose a language limitation, 
planning to translate where possible. In the event, however, we were unable to arrange translation within our 
limited resources and 32 non-English papers were excluded. We had planned to check the Global Health Data 
Exchange website (http://ghdx.healthdata.org) for additional studies, but our checks for the four RESPIRE 
countries did not identify any new publications. We emailed thirteen authors to get full text articles, however 
only two authors responded.
In this review we aimed to scope surveys conducted in LMICs, but some multi-country surveys (eg, BOLD stud-
ies) took place in a number of high-income countries as well as several LMICs. Similarly, we were interested in 
surveys of CRD in adults, but some articles also included children. However, our interest was in the methodology 
used, which remained applicable. Even though we took steps to ensure that reviewers had at least 90% agreement 
in data extraction, individual reviewers’ interpretation of methodological framework could be a source of bias. 
We did not search for health economic evaluations, though we included ‘cost’ as a search term, which limits the 
conclusions we can draw about socio-economic impact. Studies from the same study population were reported 
as independent studies; it is possible that study populations and similar processes were duplicated.
CONCLUSION
Accurate prevalence and disease burden information is important to understand the impact of CRDs on dis-
ability, quality of life, and to help influence public health care planning. Our scoping review identified several 
prevalence surveys for CRDs from a wide range of LMIC countries, but with substantial heterogeneity across 
the definitions, methodologies, instruments and types of outcomes used. Surveys remain the most practical 
approach for estimating the prevalence of CRD but there is a need to identify the most predictive questions for 
diagnosis asthma and to standardise diagnostic criteria. To reflect the true burden of CRDs in LMICs, future 
work should identify the wide range of conditions (not just asthma or COPD), and capture information on the 
burden of disease on an individual’s quality of life and the societal burden.
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